253 related articles for article (PubMed ID: 34287098)
21. Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?
Uzuncakmak TK; Özkoca D; Askin O; Kutlubay Z
Dermatol Ther; 2021 Jan; 34(1):e14647. PubMed ID: 33296557
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study.
Toosi R; Mahmoudi H; Balighi K; Teimourpour A; Alaeen H; Shaghaghi M; Abedini R; Daneshpazhooh M
J Dermatolog Treat; 2021 Feb; 32(1):33-40. PubMed ID: 31074302
[No Abstract] [Full Text] [Related]
23. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
[TBL] [Abstract][Full Text] [Related]
24. Rituximab: A Review in Pemphigus Vulgaris.
Frampton JE
Am J Clin Dermatol; 2020 Feb; 21(1):149-156. PubMed ID: 31838645
[TBL] [Abstract][Full Text] [Related]
25. Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients.
Kianfar N; Dasdar S; Mahmoudi H; Tavakolpour S; Balighi K; Daneshpazhooh M
J Dermatolog Treat; 2022 Mar; 33(2):869-874. PubMed ID: 32589481
[TBL] [Abstract][Full Text] [Related]
26. Low-dose rituximab is effective in pemphigus.
Horváth B; Huizinga J; Pas HH; Mulder AB; Jonkman MF
Br J Dermatol; 2012 Feb; 166(2):405-12. PubMed ID: 21967609
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: A retrospective single-center review of up to 68 months follow-up.
De D; Bishnoi A; Handa S; Mahapatra T; Mahajan R
Indian J Dermatol Venereol Leprol; 2020; 86(1):39-44. PubMed ID: 31089006
[TBL] [Abstract][Full Text] [Related]
28. Low-dose rituximab as an adjuvant therapy in pemphigus.
Gupta J; Raval RC; Shah AN; Solanki RB; Patel DD; Shah KB; Badheka AD; Shah KB; Aggarwal NK; Ravishankar V
Indian J Dermatol Venereol Leprol; 2017; 83(3):317-325. PubMed ID: 28366912
[TBL] [Abstract][Full Text] [Related]
29. Quality of life remains poor for patients with pemphigus vulgaris despite targeted therapies.
Schultz B; Latour E; Fett N
Br J Dermatol; 2019 Nov; 181(5):1101-1103. PubMed ID: 31127954
[No Abstract] [Full Text] [Related]
30. Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients.
Keeley JM; Bevans SL; Jaleel T; Sami N
J Dermatolog Treat; 2019 Jun; 30(4):340-345. PubMed ID: 30086663
[No Abstract] [Full Text] [Related]
31. Comparison of the efficacy and cost-effectiveness of an immunologically targeted low-dose rituximab protocol with the conventional rheumatoid arthritis protocol in severe pemphigus.
Singh N; Handa S; Mahajan R; Sachdeva N; De D
Clin Exp Dermatol; 2022 Aug; 47(8):1508-1516. PubMed ID: 35384021
[TBL] [Abstract][Full Text] [Related]
32. Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab.
Balighi K; Sakhi RS; Daneshpazhooh M; Mahmoudi H; Teimourpour A; Tavakolpour S
Dermatol Ther; 2018 Nov; 31(6):e12671. PubMed ID: 30246907
[No Abstract] [Full Text] [Related]
33. Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial.
Mignard C; Maho-Vaillant M; Golinski ML; Balayé P; Prost-Squarcioni C; Houivet E; Calbo SB; Labeille B; Picard-Dahan C; Konstantinou MP; Chaby G; Richard MA; Bouaziz JD; Duvert-Lehembre S; Delaporte E; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bédane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Joly P; Hébert V;
JAMA Dermatol; 2020 May; 156(5):545-552. PubMed ID: 32186656
[TBL] [Abstract][Full Text] [Related]
34. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.
Chen DM; Odueyungbo A; Csinady E; Gearhart L; Lehane P; Cheu M; Maho-Vaillant M; Prost-Squarcioni C; Hebert V; Houivet E; Calbo S; Caillot F; Golinski ML; Labeille B; Picard-Dahan C; Paul C; Richard MA; Bouaziz JD; Duvert-Lehembre S; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Delaporte E; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bedane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Musette P; Joly P;
Br J Dermatol; 2020 May; 182(5):1111-1119. PubMed ID: 31487383
[TBL] [Abstract][Full Text] [Related]
35. Crescendo response to rituximab in oral pemphigus vulgaris: a case with 7-year follow-up.
Greenblatt DT; Benton EC; Groves RW; Setterfield JF
Clin Exp Dermatol; 2016 Jul; 41(5):529-32. PubMed ID: 27061201
[TBL] [Abstract][Full Text] [Related]
36. Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab.
Sinagra JL; Vedovelli C; Binazzi R; Salemme A; Moro F; Mazzanti C; Didona B; Di Zenzo G
Front Immunol; 2021; 12():665522. PubMed ID: 33936104
[TBL] [Abstract][Full Text] [Related]
37. De-escalation of anti-CD20 monoclonal antibody (Rituximab) protocols in Pemphigus Vulgaris - a systematic review.
McClatchy J; Yap T; Koo K; Kern JS; Scardamaglia L
Expert Opin Biol Ther; 2021 Dec; 21(12):1591-1601. PubMed ID: 34092162
[No Abstract] [Full Text] [Related]
38. Severe multi-resistant pemphigus vulgaris: prolonged remission with a single cycle of rituximab.
Corral IS; Freitas TH; Aquino RT; Koller DA; Magliari ME; Muller H
An Bras Dermatol; 2013; 88(4):639-42. PubMed ID: 24068143
[TBL] [Abstract][Full Text] [Related]
39. An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab.
Amber KT; Hertl M
J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):777-82. PubMed ID: 25185723
[TBL] [Abstract][Full Text] [Related]
40. Intralesional injection of biosimilar rituximab in recalcitrant mucocutaneous lesions of patients with pemphigus vulgaris: A pilot study.
Mazloom E; Daneshpazhooh M; Shokouhi Shoormasti R; Balighi K; Mahmoudi H; Moradi Ketisari M; Eslami Faresani V; Ghandi N
Dermatol Ther; 2020 Nov; 33(6):e14407. PubMed ID: 33051954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
